Biotechnology · Denver, Colorado, United States
$1.95
-2.01% (-$0.04)2026-07-10
Smart-Money SignalDistribution · 42/100— Insiders are net sellers over 90 days (-$248K, 7 sales vs 12 buys)
Revenue$0
Net Income-$9.6M
EPS$-0.05
Market Cap$326.5M
Price Performance
Historical data including institutional events
Company Profile
J
J. Finley
CEO & Executive Director
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohnâs disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
- Founded
- 1996
- Employees
- 8
- Headquarters
- Denver, Colorado, United States
- Website
- www.palisadebio.com
Peer ComparisonRevenue ($B)
▾Loading company sections...